Sign up Australia
Proactive Investors - Run By Investors For Investors

BioCryst Pharmaceuticals and Idera call it quits on merger

BioCryst shareholders voted overwhelmingly to torpedo the deal
Test tubes
Idera shares are trading sharply lower on the news

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) has called it quits on its previously announced plan to merge with Idera Pharmaceuticals Inc (NASDAQ:IDRA) and create a company focused on rare diseases.

The deal was killed on Tuesday after shareholders in BioCryst, which is based in Durham, North Carolina, voted to torpedo the merger. Nearly 51mln shares of BioCryst were cast against the deal of some 83.4mln shares represented, according to a filing with the Securities and Exchange Commission.

A sizeable majority of shareholders of Exton, Pennsylvania-based Idera, meanwhile, backed the merger in its special meeting, which was also held July 10.

“The Board and shareholders of Idera overwhelmingly supported the proposed merger with BioCryst based on the strategic rationale, operating synergies and opportunity to create a stronger and more diversified rare-disease, focused organization,” said Vincent Milano, Idera’s CEO, in a statement.

READ: BioCryst Pharmaceuticals and Idera to merge and advance clinical programmes

Idera and BioCryst agreed to a merger last January in a bid to combine forces in the battle against rare diseases and focus together on their late-stage clinical trials.

In the wake of the derailed merger, Milano said Idera would remain focused on the development of its drug tilsotolimod, which targets anti-PD-1 refractory melanoma as well as solid tumor cancers.

Under the deal’s terms, BioCryst owes Idera $6mln for transaction expenses.

Analysts weigh in

Analysts were not surprised by the failure of the tie-up, with Lisa Bayko of JMP Securities suggesting BioCryst’s shareholders had doubts about the Phase 2 trial failure of Idera’s treatment IMO-8400 for dermatomyositis, a rare inflammatory skin and muscle disease.

JMP’s Bayko is keeping an Outperform rating and $12 price target on BioCryst shares as she is bullish on its lead drug BCX7353, which is in Phase 3 studies for the treatment of hereditary angioedema, a rare inherited disorder characterized by recurrent episodes of severe swelling.

Michael Ulz, a senior research analyst with Baird Equity Research, also said “termination of the agreement is not surprising”.

Ulz argues that Idera’s focus will shift back to tilsotolimod, which he views as “promising." Baird has an Outperform rating and a US$4 price target on the stock.

View full BCRX profile View Profile

BioCryst Pharmaceuticals Timeline

February 09 2016

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
picture of cannabis plants
March 24 2018
Control of the supply chain offers operational advantages and financial benefits.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use